The Wegovy weight loss curve: how progress typically unfolds week by week

Step one: the adjustment phase (weeks one to four at 0.25 mg)

The titration schedule for Wegovy begins at 0.25 mg once weekly. This dose is not intended to produce significant weight loss; its job is to let your body adapt to semaglutide without being overwhelmed by side effects. A question our prescribers hear most weeks is why weight barely moves in the first month, and the honest answer is that it is not supposed to, not meaningfully. The 0.25 mg pen is a settling-in period.

During these early weeks, gastrointestinal effects such as nausea, reduced appetite and some fatigue are common and usually most noticeable in the first few days after each injection. They tend to ease as the body adjusts. Weight may drop a little, particularly if appetite is noticeably reduced, but a 0.5 to 1 kg change is a more typical expectation than anything dramatic. The NHS patient information for semaglutide, which explains how the active ingredient works and what to expect during treatment, covers this titration approach clearly and is worth reading alongside your patient leaflet. What matters at this stage is tolerating the medicine well enough to move to the next step.

If you are thinking about how long Wegovy takes to work, this first phase is essentially the runway, not the flight.

Step two: building momentum through the titration period (months two to five)

The titration schedule moves through 0.5 mg, 1.0 mg and then 1.7 mg, each held for roughly four weeks before the prescriber assesses whether to increase the dose. This is where most people see the curve begin to steepen. Appetite suppression becomes more noticeable, portion sizes feel smaller without effort and the cumulative calorie deficit starts to register on the scales.

In the STEP 1 clinical trial, published in the New England Journal of Medicine, participants lost on average around 15% of body weight over 68 weeks at the 2.4 mg maintenance dose. The bulk of that loss accumulated during and after the titration period, not in the first month. By week 20 most participants had reached the maintenance dose and were well into the steepest part of their individual curve.

Lifestyle changes make a real difference here. If you want a fuller picture of what the weight loss medication Wegovy involves, including how it is prescribed and who it suits, the lifestyle component matters more as the dose rises and appetite suppression becomes the dominant driver. If you are also looking at the broader picture of how semaglutide produces weight loss and what the clinical evidence shows about the results people can expect, that context sits alongside the clinical evidence well.

Dose increases are always a clinical decision, made by your prescriber based on how you are tolerating the medicine and your progress. Nobody should be increasing their dose on their own schedule.

Step three: the maintenance phase and the plateau (months five onward at 2.4 mg)

Once 2.4 mg is reached, the rate of weight loss typically slows and, for many people, eventually levels off into a plateau. This is not treatment failure. It is the expected shape of the curve, and it mirrors what happened in the STEP 1 trial population. The body reaches a new energy balance at a lower weight and a lower appetite, and the scales stop moving as sharply.

A plateau at this stage is worth discussing with your prescriber rather than assuming the medicine has stopped working. Small adjustments to diet composition, activity level or meal timing can restart progress. Some people, after clinical discussion, go on to consider the 7.2 mg semaglutide pen, which the MHRA approved in April 2026 for adults with a BMI of 30 or above and which trials found produced around 20.7% average weight loss over 72 weeks. Whether that is appropriate is entirely a prescriber's assessment, not a decision to make alone.

It is also worth reading NICE's published guidance on semaglutide, TA875, which sets out the clinical framework and notes that continuing treatment is reviewed if progress does not meet the expected threshold after six months on the maintenance dose. Understanding that framework helps set realistic expectations for the plateau stage.

One practical thing: the curve looks different on paper than it feels in daily life. People often notice changes in how clothes fit, how much they eat at a sitting and how their energy levels shift before the scales reflect it. Those signals matter too.

When progress feels slower than expected

If weight loss feels slower than expected, there are a few questions worth considering before assuming something is wrong. Is the dose still at a lower titration level? Has lifestyle support, including realistic dietary changes, actually been implemented? Are there any medicines being taken alongside Wegovy that could interact? And has enough time passed to judge fairly, because the curve is measured in months, not weeks.

Our page covering weight and Wegovy, including how the medicine interacts with your body's weight regulation, includes useful detail on what the evidence does and does not promise. If you are comparing options or wondering whether a different medicine might suit you better, the weight loss treatment overview on this site covers the licensed options in plain terms.

For anyone who has had no measurable progress despite reaching the maintenance dose and making meaningful lifestyle changes, this is a conversation to have with the prescriber, not something to troubleshoot through dose adjustment on your own. You can also report any suspected side effects via the MHRA Yellow Card scheme, which is open to patients.

If you would like to discuss your own situation, including whether Wegovy weight loss is clinically suitable for you or how your current progress compares with the expected curve, speak to our prescribers through a free consultation. Every case is reviewed personally by a GPhC-registered Independent Prescriber, not automated software.